These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11323200)

  • 21. The use of pharmacokinetics as an interpretive and predictive tool in chemical toxicology testing and risk assessment: a position paper on the appropriate use of pharmacokinetics in chemical toxicology.
    Frantz SW; Beatty PW; English JC; Hundley SG; Wilson AG
    Regul Toxicol Pharmacol; 1994 Jun; 19(3):317-37. PubMed ID: 8090955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health related guide values for drinking-water since 1993 as guidance to assess presence of new analytes in drinking-water.
    Dieter HH
    Int J Hyg Environ Health; 2014 Mar; 217(2-3):117-32. PubMed ID: 23820379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonlinear mixed-effects models for pharmacokinetic data analysis: assessment of the random-effects distribution.
    Drikvandi R
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):223-232. PubMed ID: 28194555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics. A regulatory perspective.
    Sun H; Fadiran EO; Jones CD; Lesko L; Huang SM; Higgins K; Hu C; Machado S; Maldonado S; Williams R; Hossain M; Ette EI
    Clin Pharmacokinet; 1999 Jul; 37(1):41-58. PubMed ID: 10451782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicodynamic modelling and the interpretation of in vitro toxicity data.
    Blaauboer BJ
    Toxicol Lett; 2001 Mar; 120(1-3):111-23. PubMed ID: 11323168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Balancing Blood Sample Volume with 3Rs: Implementation and Best Practices for Small Molecule Toxicokinetic Assessments in Rats.
    Harstad E; Andaya R; Couch J; Ding X; Liang X; Liederer BM; Messick K; Nguyen T; Schweiger M; Tarrant J; Zhong S; Dean B
    ILAR J; 2016 Dec; 57(2):157-165. PubMed ID: 28053069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of toxicokinetics in toxicity studies--Toxicokinetics of 4-methylanisole and its metabolites in juvenile and adult rats.
    Brandon EF; van Kesteren PC; van Eijkeren JC; Tienstra M; Sanchez PL; Tonk EC; Piersma AH; Bos PM
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):55-64. PubMed ID: 26140820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based toxicology: a comprehensive framework for causation.
    Guzelian PS; Victoroff MS; Halmes NC; James RC; Guzelian CP
    Hum Exp Toxicol; 2005 Apr; 24(4):161-201. PubMed ID: 15957536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilizing relative potency factors (RPF) and threshold of toxicological concern (TTC) concepts to assess hazard and human risk assessment profiles of environmental metabolites: a case study.
    Terry C; Rasoulpour RJ; Knowles S; Billington R
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):301-17. PubMed ID: 25584438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of population pharmacokinetics in drug development.
    Vozeh S; Steimer JL; Rowland M; Morselli P; Mentre F; Balant LP; Aarons L
    Clin Pharmacokinet; 1996 Feb; 30(2):81-93. PubMed ID: 8906893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What happens in the skin? Integrating skin permeation kinetics into studies of developmental and reproductive toxicity following topical exposure.
    Dancik Y; Bigliardi PL; Bigliardi-Qi M
    Reprod Toxicol; 2015 Dec; 58():252-81. PubMed ID: 26475253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
    Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
    Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current status of exposure-driven approaches for chemical safety assessment: A cross-sector perspective.
    Sewell F; Aggarwal M; Bachler G; Broadmeadow A; Gellatly N; Moore E; Robinson S; Rooseboom M; Stevens A; Terry C; Burden N
    Toxicology; 2017 Aug; 389():109-117. PubMed ID: 28774667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicodynetics: A new discipline in clinical toxicology.
    Baud FJ; Houzé P; Villa A; Borron SW; Carli P
    Ann Pharm Fr; 2016 May; 74(3):173-89. PubMed ID: 27107462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resampling methods in sparse sampling situations in preclinical pharmacokinetic studies.
    Mager H; Göller G
    J Pharm Sci; 1998 Mar; 87(3):372-8. PubMed ID: 9523992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Demographic Toxicokinetic-Toxicodynamic Modeling of Lethal Effects.
    Gergs A; Gabsi F; Zenker A; Preuss TG
    Environ Sci Technol; 2016 Jun; 50(11):6017-24. PubMed ID: 27158745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A tiered approach to pharmacokinetic studies.
    Wilson AG; Frantz SW; Keifer LC
    Environ Health Perspect; 1994 Dec; 102 Suppl 11(Suppl 11):5-11. PubMed ID: 7737041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicokinetics in the evaluation of toxicity data.
    Watanabe PG; Schumann AM; Reitz RH
    Regul Toxicol Pharmacol; 1988 Dec; 8(4):408-13. PubMed ID: 3222482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development.
    Walker DK
    Br J Clin Pharmacol; 2004 Dec; 58(6):601-8. PubMed ID: 15563358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.